New Spherix research highlights existing need for innovation in this underserved population EXTON, Pa., May 22, 2023 — The non-alcoholic
Online platform underscores Spherix’s commitment to innovation by providing dynamic solutions generated from the company’s comprehensive insights library of reports
Recent research suggests AbbVie has managed gastroenterologists’ concerns regarding JAK safety, setting up a potentially favorable encore in the Crohn’s
U.S. specialists’ lack of satisfaction with current treatment options in cutaneous and discoid lupus paves the way for advanced pharmacological
An FDA approval for Entyvio SC could exacerbate an already aggressive fight for second-line UC treatments. Exton, PA., May 4,
Genentech’s first campaign for eye drug Vabysmo is literally eye-opening. In the debut TV commercial, a woman opens an eye-shaped
Use of Trudhesa as an acute migraine treatment is on par with the more-established Reyvow, though future projections have it
Although providers are optimistic about the potential of a new treatment for Alzheimer’s, some are concerned that the burden of monitoring the
U.S. neurologists are “cautiously optimistic” about using Eisai’s Leqembi in Alzheimer’s disease as concerns about safety and the need for
Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands’ use on
Release of second annual EU5 research on IgA nephropathy highlights unmet needs, regional diagnosis and treatment trends, and awareness of
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As
